ÂÜÀòÂÒÂ×

Dr. Terenzio Ignoni joined Gain Therapeutic in June 2021 as SVP Quality and CMC bringing with him more than 22 years of hands-on experience in pharmaceutical technical operations, quality, and regulatory CMC with a successful track record of drug approvals in multiple jurisdictions, notably: Europe, USA, Canada, Japan, Australia, and Latin America. Before joining Gain, Terenzio was VP Quality and QP at Jazz Pharmaceuticals (JAZZ NASDAQ), a global biopharmaceutical company focused on neuroscience and oncology rare diseases. During his tenure at Jazz, Terenzio lead product submissions, technical due diligence, and site pre-approval inspections from US-FDA, PMDA, ANVISA, EMA. Prior to Jazz Pharmaceutical, Terenzio held the position of VP Quality at Gentium a biopharmaceutical company specialized in the development and manufacturing of biopharmaceutical products. During his time at Gentium, he was in charge of the development and deployment of the quality system, technical operations (manufacturing and control), and CMC regulatory strategy leading to the EMA approval of the drug lead candidate in 2013 and of the merge of the company with Jazz Pharmaceuticals in 2014. Terenzio started his career as a Quality Control supervisor at Biosearch manufacturing (merged into Vicuron/Pfizer), a company that specialized in the development and manufacturing of antibiotics agents, and as Analytical Development & Quality Control Manager of Zambon Group (Lonigo manufacturing site). Terenzio received a Pharm.D. from the University of Turin, Italy.